<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1537">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970800</url>
  </required_header>
  <id_info>
    <org_study_id>10/01/VA03</org_study_id>
    <nct_id>NCT01970800</nct_id>
  </id_info>
  <brief_title>The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature</brief_title>
  <official_title>The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the predictive value of IGF-1 generation test for
      growth velocity during GH treatment for 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Primary Efficacy Outcome measurement</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Growth velocity after treatment with appropriate growth hormone doses</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Short Stature</condition>
  <arm_group>
    <arm_group_label>Growth hormone, injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth hormone injection 0.3mg/kg/week dailY</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months</description>
    <arm_group_label>Growth hormone, injections</arm_group_label>
    <other_name>Nutropin AQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ability to provide written informed consent

          -  Prepubertal males and females form 5- 11years old

          -  Bone age &lt;11 years in males and &lt;9 years in females

          -  Height SD score&lt;-2.25SD in males and females

          -  IGF-1SD score &lt;-1SD in both males and females

          -  Peak GH level after stimulation &gt;10ng/ml

        Exclusion Criteria:

          -  History of prior chemotherapy and or radiation

          -  Active neoplasm

          -  Pediatric patients with closed epiphyses

          -  Prader-Willi syndrome, Turner syndrome or any other genetic or chromosomal anomaly

          -  Treatment with inhaled or systemic steroids

          -  BMI &lt;5th percentile or &gt;95th percentile

          -  Tanner 2 at clinical or biochemical examination by ultrasensitive LH and FSH
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetlana Ten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Svetlana Ten, MD</last_name>
    <phone>718-283-8894</phone>
    <email>tenlana@aol.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IGF-1</keyword>
  <keyword>Short Stature</keyword>
  <keyword>GH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
